CRA assessed whether disputed representations of bioequivalence significantly affected sales of the branded product. CRA’s evaluation included consideration of distribution channels, purchase timing, and the effect of payor control mechanisms on product uptake and sales. The case ultimately resulted in a settlement.
CRA named Top 3 Litigation Dispute Advisory Services Consultant in The National Law Journal
CRA’s Chicago Practice is proud to have been ranked as one of the Top 3 Litigation Dispute Advisory Services Consultancies in The National Law Journal’s “Best...